ZYUS Life Sciences Receives Analytical Testing and Research Licences from Health Canada Further Enabling Medical Cannabis Product Development and Production
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Feb 11, 2020--
ZYUS Life Sciences Inc. (“ZYUS”), a company focused on the global development and commercialization of innovative cannabinoid-based formulations, announced that it has received both its Analytical Testing Licence and Research Licence from Health Canada in accordance with Canada’s Cannabis Act and Cannabis Regulations. The grant of these additional licenses follows the recent grant by Health Canada of ZYUS’ Standard Processing Licence for its Saskatoon-based GMP designed processing facility.
The timely award of these two important additional licenses are significant steps forward for ZYUS as the Company prepares for the near-term launch of production, clinical studies and sales of medical cannabinoid-based formulations which will enable it to leverage the power of cannabinoids to manage disease and improve patient quality of life.
With multiple licenses granted by Health Canada over the past two months, ZYUS is now authorized to perform in-house analytical testing activities on cannabis and derivative products, which will enable ZYUS to implement pharmaceutical testing standards and ensure the manufacture of its cannabis formulations are GMP compliant.
The Research Licence enables ZYUS to perform regulated plant breeding research to develop designer cannabis plants containing unique cannabinoid profiles. The research and development will further advance the science of well-being by assisting with the development of cannabinoid-based formulations, for a transformational impact on patients’ lives.
“ZYUS is dedicated to unlocking the full potential of phyto-therapeutics to manage disease, advance medicine and improve patient quality of life,” said Brent Zettl, ZYUS CEO. “These incremental licenses will provide our team of scientists, extraction experts, healthcare practitioners and quality control experts with tools to leverage their collective experience and initiate important planned research, trials and analytical testing initiatives, reduce product testing cycle times and implement pharmaceutical testing standards for ZYUS products.”
About ZYUS Life Sciences Inc.
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, gel-caps, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit www.zyus.com
This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to expectations with respect to our business plans and product lines.
Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.
Actual results could differ materially from those currently anticipated due to a number of factors and risks. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200211005358/en/
CONTACT: For further information:
ZYUS Media Inquiries
1-833-515-5500ZYUS Investor Relations
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: ALTERNATIVE MEDICINE HEALTH OTHER HEALTH OTHER SCIENCE RESEARCH SCIENCE PHARMACEUTICAL
SOURCE: ZYUS Life Sciences Inc.
Copyright Business Wire 2020.
PUB: 02/11/2020 07:25 AM/DISC: 02/11/2020 07:25 AM